Kennedy Capital Management’s Castle Biosciences CSTL Stock Holding History

Kennedy Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.31M	Buy	+348,371	New	+$7.76M	0.15%	238

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's CSTL Position: Q2 2026 in Review

Kennedy Capital Management opened a new position in Castle Biosciences (CSTL) in Q2 2026: 348,371 shares worth $8.31M. The stake represents 0.15% of the portfolio and ranks #238 among its holdings.

176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Kennedy Capital Management held 348,371 shares of Castle Biosciences worth $8.31M as of Q2 2026.
Castle Biosciences was a new Kennedy Capital Management position in Q2 2026.
Castle Biosciences made up 0.15% of Kennedy Capital Management's portfolio in Q2 2026, its #238 holding.
176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.